Ablenio is a cutting edge clinical-stage biotech
We are a publicly traded biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, Ablenio is targeting chronic diseases with large market potential and unmet medical need.
We are continuously inventing and developing novel complement-based therapies for unmet needs. Over the last decade, we have generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates. Our portfolio of therapeutic antibodies targets the chronic rare diseases of our time, and they have demonstrated a better safety and efficacy profile than currently marketed drugs. Ablenio utilizes an innovative R&D strategy, which enables us to block certain parts of the immune system involved with the development and progression of rare diseases. Our portfolio of antibodies are filtered through a unique research pattern to identify best-fit candidates for further development and to treat specific clinical indications.
We have achieved remarkable clinical success in advancing multiple antibodies that have a superior mechanism of action compared to those currently under development at other pharmaceutical companies. Our preclinical and clinical studies provide compelling evidence that these antibodies are likely to have a higher level of selectivity and efficacy than competing antibody therapies. Moreover, our antibodies have the potential to be safer due to selectivity for the alternative complement pathway.
